Recruiting PHASE2, PHASE3 Postoperative Blood Loss

New treatment option for Postoperative Blood Loss

Official title Effect of Early Administration of TXA in Adult Hip Fractures

ClinicalTrials.gov ID: NCT05047133

What this study is testing

What is Tranexamic acid?

Tranexamic acid is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for postoperative blood loss.

Also referred to as Lysteda.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients.
  • Phase 3: a large, late-stage study

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older. Healthy volunteers may be eligible.

You may be able to join if

  • 1\. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

You likely can't join if

  • Polytrauma patients
  • Previous operation on the ipsilateral hip
  • Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
  • Patients with \< 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
  • History of seizure disorder
  • Patients on birth control
See the full eligibility criteria
Who can join
  • 1\. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation
What rules you out
  • Polytrauma patients
  • Previous operation on the ipsilateral hip
  • Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
  • Patients with \< 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
  • History of seizure disorder
  • Patients on birth control
  • Pregnant Women
  • Prisoners
  • Active thromboembolic disease (DVT/PE, MI, Stroke)

The study team makes the final eligibility decision.

Where it's taking place

  • Grand Blanc, Michigan, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Grand Blanc, Michigan, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.